Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-18T08:46:03.102Z Has data issue: false hasContentIssue false

Mephenesin dependence: A case series

Published online by Cambridge University Press:  16 April 2020

S. Djezzar
Affiliation:
Addictovigilance Centre, Pôle Addictologie-Toxicologie-Psychiatrie, Paris, France
F. Vorspan
Affiliation:
Psychiatry Department, Pôle Addictologie-Toxicologie-Psychiatrie, Neuropsychopharmacologie des Addictions, INSERM U705 CNRS UMR 8206, Paris, France
D. Chataigner
Affiliation:
Poison Centre, Pôle Addictologie-Toxicologie-Psychiatrie, Hôpital Fernand Widal, APHP, Paris, France
E. Burin
Affiliation:
Addictovigilance Centre, Pôle Addictologie-Toxicologie-Psychiatrie, Paris, France
R. Garnier
Affiliation:
Poison Centre, Pôle Addictologie-Toxicologie-Psychiatrie, Hôpital Fernand Widal, APHP, Paris, France
J.-P. Lépine
Affiliation:
Psychiatry Department, Pôle Addictologie-Toxicologie-Psychiatrie, Neuropsychopharmacologie des Addictions, INSERM U705 CNRS UMR 8206, Paris, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Mephenesin is a central muscle relaxant, acting through a depression of the activity of some neurones in the caudate nucleus. It was proposed as a potential treatment of alcohol withdrawal syndrome in the 50s. This over the counter medicine is now mainly prescribed to treat spasticity or as an adjunctive treatment of painful muscle spasm. We know little about this substance except that side effects are venous thrombosis, haemolysis or cutaneous intolerance. Yet, no case of abuse or dependence has been reported.

Aims

To report a series of 5 clinical cases in patients who developed abuse or dependence to mephenesin.

Methods

We performed a systematic search in data bases of both Paris addictovigilance and poison centres from 1999 to 2010. Clinical details were obtained from clinicians when possible. A literature search was also performed to describe mephenesin mechanisms of actions that could be implied.

Results

Three (3) women et 2 men aged 35 to 52 years (m : 43.6) were identified as abusing mephenesin, among which 4 patients had a full DSM IV criteria of dependence. All had a previous history of abuse or substance dependence (alcohol, heroin, codeine, ketamine…).The average mephenesin daily intake was 13 g (9 to 24 g) when the maximum recommended dosage is 3 gr/d. In one case, a withdrawal syndrome was observed (tremor, aggressiveness).

Conclusion

Mephenesin may be abused by patients with previous risk factors, especially a personal history of alcohol dependence.

Type
P01-29
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.